Lexicon Pharma (LXRX) Shares Surge as Stifel Nicolaus Adds to 'Select List,' Boosts Price Target

Article Stock Quotes (1) Comments (0)

Shares of Lexicon Pharma (NASDAQ: LXRX) have risen sharply Tuesday morning following some earlier optimism from Stifel Nicolaus' Stephen Willey. The stock last traded at $2.14, up nearly 10 percent from Monday's close.

In addition to a raised price target, Willey also added shares to the firm's "Select List." The analyst now sees shares of Lexicon rising to $4 over the next year, up from $3 previously. Willey maintains a Buy rating on the stock.

The bullishness follows statistically significant data from LX4211 Phase 2b trial of HbA1c.

For an analyst ratings summary and ratings history on Lexicon Pharmaceuticals click here. For more ratings news on Lexicon Pharmaceuticals click here.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Jefferies Bumps Zumiez (ZUMZ) Numbers Up, But Remains on Sidelines
• Williams-Sonoma (WSM) Delivers 'Clean' Q1 Beat - Analyst
• Janney Capital Boosts PT on Gap (GPS) Post Q1

Create E-mail Alert Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Stifel Nicolaus

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?